KRAS and non-small cell lung carcinoma: A cohort study comparing ICIs monotherapy with chemoimmunotherapy for NSCLC patients showed a better rate of survival in KRAS-mutant patients than wild-type patients, yet no significant difference was found between treatment strategies in the subgroup of KRAS-mutant patients [73].